BOSTON, MA--(Marketwired - Jul 15, 2015) - The Eventide Gilead Fund (
The Eventide Funds are managed by Eventide Asset Management, LLC, a Boston-based Registered Investment Advisor practicing values-based investing.
"We're very pleased with the performance and recognition, and consider it validation of our core belief that stakeholder value creation can lead to sustainable shareholder value creation," commented Eventide CEO Robin John. He explained, "For Eventide, part of developing conviction in an investment, alongside industry expert views, participation in secular investment winds, superior management teams, and sound fundamentals, is understanding the nature of service at a company with respect to key stakeholder groups -- customers and employees especially, but also the environment, among others. Value creation, we believe, is an underappreciated source of investment alpha, and is explanatory of Eventide's success since inception."
The following table shows the performance of the Funds since inception:
| As of 6/30/2015 | YTD return | 1 year return | 3 year annualized return | 5 year annualized return | Since inception (07/08/2008) annualized return |
| Eventide Gilead Fund* | 10.53% | 18.20% | 29.30% | 25.17% | 18.09% |
| Russell Mid-Cap Growth Total Return Index | 4.18% | 9.45% | 19.24% | 18.69% | 10.87% |
| S&P 500 Total Return Index | 1.23% | 7.42% | 17.31% | 17.34% | 9.52% |
| As of 6/30/2015 | YTD return | 1 year return | Since inception (12/27/2012) annualized return |
| Eventide Healthcare & Life Sciences Fund* | 24.69% | 49.23% | 46.76% |
| Healthcare Blended Index | 18.05% | 31.39% | 34.60% |
| S&P 500 Total Return Index | 1.23% | 7.42% | 18.56% |
The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the funds' prospectus for more information regarding the funds' fees and expenses. Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).
Eventide Gilead Fund expenses: Total Expenses 1.45%. Eventide Healthcare & Life Sciences Fund expenses: Gross Expenses 1.70%; Net Expenses 1.64%. The advisor has contractually agreed to waive fees and/or reimburse expenses of the Fund through 31 October 2015. The agreement may only be terminated by the Fund's Board of Trustees on 60 days' written notice.
Between the two Funds, Eventide manages $2.3 billion in net assets, and plans to launch a third Fund -- the Eventide Multi-Asset Income Fund -- later this month.
Wall Street Journal rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. The Eventide Gilead Fund ranked #2 out of 369 Mid-Cap Growth funds (Lipper data) for the 3-yr period based on total returns and #2 out of 333 Mid-Cap Growth funds (Lipper data) for the 5-yr period based on total returns.
The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index. Investors cannot directly invest in an index; unmanaged index returns do not reflect any fees, expenses or sales charges.
Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds' ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.
An investor should consider the Funds' investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds' prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836) or visit www.eventidefunds.com. Eventide Funds are distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.
4478-NLD-7/15/2015
Contact Information:
Fund Contact:
Jason Myhre
877-771-EVEN (3836)